EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial

Axel Hauschild iD, Jessica Cecile Hassel iD, Mirjana Ziemer, Piotr Rutkowski iD, Friedegund Meier iD, Lukas Flatz iD, Caroline Gaudy-Marqueste, Mario Santinami iD, Francesco Russano iD, Imke von Wasielewski, Thomas Eigentler, Michele Maio iD und 14 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-00852 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Axel Hauschild und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Interleukin-2, Melanoma, Neoadjuvant Therapy, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier: NCT02938299 ). The trial enrolled 256 patients in the European Union and met its primary end point, demonstrating a statistically significant improvement in recurrence-free survival (RFS; hazard ratio, 0.59; P = .005) for daromun followed by surgery versus up-front surgery, at a median follow-up (FU) of 21 months from random assignment. PIVOTAL included two clinically distinct subgroups, namely, patients with de novo diagnosed metastatic disease (n = 34; 13%) and patients with recurrence(s) after surgery with or without radiotherapy and/or adjuvant systemic therapies (n = 222; 87%). Here, we present an updated analysis of the primary and secondary end points, including safety data, at a median FU of 36.8 months from random assignment (database cutoff: November 28, 2025), alongside new sensitivity analyses of event-free survival (EFS). The updated analysis confirms the clinically and statistically meaningful improvements in RFS and distant metastasis-free survival recorded in the neoadjuvant daromun versus control arm. The EFS post hoc analysis, conducted in both the overall population and the recurrent patient subgroups (with or without prior systemic therapies), provides consistency and robustness to the benefit of neoadjuvant daromun observed for the primary efficacy end point. No new safety signals of concern were recorded.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2MelanomaNeoadjuvant TherapySkin NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedInjections, IntralesionalNeoplasm Recurrence, LocalNeoplasm Staging

Substanzen

Interleukin-2

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
  • Department of Dermatology and NCT, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
  • Skin Cancer Center, University Hospital Leipzig, Leipzig, Germany.
  • Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
  • Department of Dermatology, Center for Dermatooncology, Eberhard Karls University of Tübingen, Tübingen, Germany.

ORCID-Profile: Axel Hauschild, Jessica Cecile Hassel, Piotr Rutkowski, Friedegund Meier, Lukas Flatz, Mario Santinami, Francesco Russano, Michele Maio, Iris Zalaudek, Sebastian Haferkamp, Michael Weichenthal, Paolo Antonio Ascierto, Caroline Robert, Dirk Schadendorf

Zitieren

APA

Hauschild, A., Hassel, J. C., Ziemer, M., Rutkowski, P., Meier, F., Flatz, L., Gaudy-Marqueste, C., Santinami, M., Russano, F., von Wasielewski, I., Eigentler, T., Maio, M., Zalaudek, I., Haferkamp, S., Quaglino, P., Welzel, J., Weichenthal, M., Elia, G., Covelli, A., …, & Kaehler, K. C. (2026). Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00852

Vancouver

Hauschild A, Hassel JC, Ziemer M, Rutkowski P, Meier F, Flatz L, et al. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00852

BibTeX
@article{Hauschild2026,
  author = {Hauschild, Axel and Hassel, Jessica Cecile and Ziemer, Mirjana and Rutkowski, Piotr and Meier, Friedegund and Flatz, Lukas and Gaudy-Marqueste, Caroline and Santinami, Mario and Russano, Francesco and von Wasielewski, Imke and Eigentler, Thomas and Maio, Michele and Zalaudek, Iris and Haferkamp, Sebastian and Quaglino, Pietro and Welzel, Julia and Weichenthal, Michael and Elia, Giuliano and Covelli, Alfredo and Lorizzo, Katia and Parca, Agnese and Neri, Dario and Ascierto, Paolo Antonio and Robert, Caroline and Schadendorf, Dirk and Kaehler, Katharina Charlotte},
  title = {Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00852}
}
Kostenlos starten →